KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBIT Margin (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of EBIT Margin data on record, last reported at 4442.9% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 449182.0% year-over-year to 4442.9%; the TTM value through Dec 2025 reached 67.98%, up 3102.0%, while the annual FY2025 figure was 2211.12%, 227850.0% up from the prior year.
  • EBIT Margin reached 4442.9% in Q4 2025 per IONS's latest filing, up from 102.21% in the prior quarter.
  • Across five years, EBIT Margin topped out at 4442.9% in Q4 2025 and bottomed at 220303.33% in Q2 2024.
  • Average EBIT Margin over 5 years is 10932.78%, with a median of 73.16% recorded in 2021.
  • Peak YoY movement for EBIT Margin: tumbled -22025546bps in 2024, then surged 22035363bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 367.67% in 2021, then tumbled by -137bps to 136.95% in 2022, then surged by 162bps to 85.51% in 2023, then tumbled by -157bps to 48.91% in 2024, then skyrocketed by 9184bps to 4442.9% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 4442.9% in Q4 2025, 102.21% in Q3 2025, and 50.29% in Q2 2025.